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NANOPARTICLE FOR TARGETING BRAIN ing significant myelosuppression in combination with TMZ . 
TUMORS AND DELIVERY OF Hence , prognosis remains dismal with only 2 % of patients 
06 - BENZYLGUANINE surviving 5 years . This necessitates the development of 
novel therapeutic agents that can circumvent resistance 
CROSS - REFERENCE TO RELATED 5 mediated by tumor biology ( e . g . , drug resistance due to 
APPLICATION DNA repair ) and by normal physicological barriers ( e . g . , 
BBB ) . 
This application claims the benefit of U . S . Patent Appli - Despite the advances in the treatment of GBM noted 
cation No . 61 / 804 , 033 , filed Mar . 21 , 2013 , expressly incor - above and in view of the GBM resistance to TMZ , a need 
porated herein by reference in its entirety . exists for effective compositions and methods for treating 
GBM . The present invention seeks to fulfill this need and STATEMENT OF GOVERNMENT LICENSE provides further related advantages . RIGHTS 
SUMMARY OF THE INVENTION This invention was made with Government support under 15 
Grant Nos . R01 CA161953 , R01 CA134213 , RO1 The present invention provides a nanoparticle having a EB006043 , and T32 CA138312 , awarded by the National 
Institutes of Health . The government has certain rights in the crosslinked chitosan - polyethylene oxide oligomer copoly 
invention . mer coating to which O® - benzylguanine is covalently 20 coupled . Compositions that include the nanoparticle and 
BACKGROUND OF THE INVENTION methods for using the nanoparticle are also provided . In one aspect , the invention provides a nanoparticle . In 
Multifunctional nanoparticles ( NPs ) that enable diagnos - one embodiment , the nanoparticle includes 
tic imaging and therapeutic drug delivery are rapidly emerg ( a ) a core having a surface and comprising a core material ; 
ing as a powerful platform for cancer therapy . The ability to 25 ( b ) a coating on the surface of the core , the coating 
monitor drug delivery non - invasively in situ will provide comprising a crosslinked copolymer comprising a chitosan 
clinicians with an unprecedented tool that may facilitate and a poly ( ethylene oxide ) oligomer ; and 
personalized therapeutic regimens for each patient ' s tumor . ( c ) O® - benzylguanine covalently coupled to the coating . 
Additionally , NPs are attractive as drug delivery vehicles The crosslinked polymer includes crosslinks that are 
because they can deliver potent doses of therapeutic agents 30 glutathione - sensitive crosslinks . Representative crosslinks 
to cancer cells with significantly improved specificity and include disulfide crosslinks . Disulfide crosslinks are reduced reduced toxicities . These advantages are achieved through to dithiols in glutathione - containing environments . to dithiols targeted delivery and release of chemotherapeutics specifi In certain embodiments , nanoparticle is magnetic nano 
cally in tumor cells . Furthermore , NPs can be engineered to particle having a core material that is a magnetic material . bypass biological barriers such as the blood - brain barrier 35 In certain embodiments , the nanoparticle of the invention ( BBB ) , which normally prevents the passage of more than further includes a targeting agent . Suitable targeting agents 98 % of drugs to the brain and achieve desirable biodistri 
bution profiles that minimize chemotherapy side effects . include small organic molecules , peptides , proteins , and 
Proper integration of these favorable attributes in a single nucleic acids . In one embodiment , the targeting agent is 
nanoparticle formulation is expected to offer a solution for 40 chlorotoxin , or a variant or derivative thereof . 
highly intractable cancers such as glioblastoma multiforme In certain embodiments , the nanoparticle of the invention 
( GBM ) . further includes a diagnostic agent . Suitable diagnostic 
GBMs are malignant brain tumors that are among the agents include fluorescent agents , such as visible or near 
most lethal cancers , striking 14 , 000 individuals in the U . S . infrared fluorescent agents . 
each year . Therapy has long included surgery followed by 45 In certain embodiments , the nanoparticle of the invention 
conformal radiotherapy . Recent clinical trials have docu - includes a targeting agent and a diagnostic agent . 
mented that inclusion of the DNA methylating agent temo - In another aspect of the invention , nanoparticle compo 
zolomide ( TMZ ) in the post - operative therapy of newly sitions are provided . Nanoparticle compositions include a 
diagnosed GBMs has produced the first significant improve - nanoparticle of the invention and a carrier suitable for 
ment in survival in the last 30 years . The clinical efficacy of 50 administration to a subject . Carriers include those suitable 
TMZ reflects , in part , its ability to cross the BBB . Clinical for intravenous injection and nasal delivery . 
outcome , however , is not improved by TMZ in the majority In a further aspect , the invention provides a method for 
of GBMs because of resistance mediated in large part by introducing Oº - benzyguanine into a cell . In the method , a 
Oº - methylguanine - DNA methyltransferase ( MGMT ) , a cell is contacted with a nanoparticle of the invention . In 
DNA repair protein that removes the cytotoxic O® - methyl - 55 certain embodiments , the cell is a brain cancer cell . 
guanine lesions produced by TMZ . In another aspect of the invention , methods for detecting 
In vitro studies suggest that GBM resistance to TMZ can cells or tissues by magnetic resonance imaging . In one 
be overcome by ablating MGMT activity with DNA repair embodiment , the method includes 
inhibitors such as Oº - benzylguanine ( BG ) . BG serves as a ( a ) contacting cells or tissues of interest with a nanopar 
pseudo - substrate for MGMT and irreversibly inactivates the 60 ticle of the invention having affinity and specificity for the 
DNA repair protein . However , clinical trials have shown that cells or tissues of interest ; and 
inclusion of BG in TMZ treatment regimens reduces the ( b ) measuring the level of binding of the nanoparticle , 
maximum tolerated dose ( MTD ) of TMZ by 50 % . The wherein an elevated level of binding , relative to normal cells 
significant reduction in MTD is primarily caused by the poor or tissues , is indicative of binding to the cells or tissues of 
pharmacokinetics of BG ; BG poorly permeates across the 65 interest . 
BBB , is limited by a short blood half - life , and rapidly In a further aspect , the invention provides methods for 
accumulates in clearance organs and bone marrow produc - treating a tissue . In one embodiment , the method includes 
m 
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contacting a tissue of interest with a nanoparticle of the stained polyacrylamide gel electrophoresis image of NPCP 
invention . In certain embodiments , the tissue of interest is BG - CTX incubated for 1 hour under blood conditions ( BC ) 
brain tissue . or intracellular conditions ( IC ) showing pH and glutathione 
In yet another aspect of the invention , methods for inhib - sensitive degradation of the chitosan - g - PEG coating from 
iting O ' - methylguanine - DNA methyltransferase ( MGMT ) 5 NP . FIG . 3B compares drug release profiles showing the pH 
in a subject are provided . In one embodiment , the method and glutathione sensitive release of BG from NPCP - BG 
includes administering a nanoparticle of the invention to the CTX . BC = pH 7 . 4 and no glutathione . IC = pH 5 . 0 and 100 
subject . mM glutathione . 
In another aspect , the invention provides methods for FIG . 4 shows confocal fluorescence images of treated 
treating a disease or condition treatable by inhibiting 10 SF767 cells . Cells were imaged 24 hours post treatment with 
0° - methylguanine - DNA methyltransferase ( MGMT ) , com - NPCP - AF647 - CTX ( fluorophore labeled NPs ) , NPCP - ( BG 
prising administering a therapeutically effective amount of a AF647 ) - CTX ( NPs loaded with fluorophore labeled BG ) , 
nanoparticle of the invention to a subject in need thereof . and BG - AF647 ( fluorophore labeled BG ) . Cell nuclei are 
In a further aspect of the invention , methods for treating shown in blue , cell membranes in green , and NPCP - AF647 
a brain cancer are provided . In one embodiment , the method 15 CTX or BG - AF647 in red . The scale bar corresponds to 10 
includes administering a therapeutically effective amount of um . 
a nanoparticle of the invention to a subject in need thereof . FIG . 5 compares suppression of MGMT activity in SF767 
In one embodiment , the brain cancer is glioblastoma mul - cells treated with BG or NPCP - BG . Cells were harvested 2 
tiforme . In another embodiment , the brain cancer is a hr and 24 hr after inhibitor exposure and MGMT activity 
TMZ - resistant brain cancer . 20 determined in cleared supernatants of whole cell homoge 
In another aspect , the invention provides method for nates by quantitating transfer of radioactivity from DNA 
treating a brain cancer that include administering a thera - containing Oº - [ H ] methylguanine to protein . Data represent 
peutically effective amount of TMZ and a therapeutically the results of cells treated with a single preparation of 
effective amount of a nanoparticle of the invention to a NPCP - BG and are representative of results observed using 
subject in need thereof . In one embodiment , TMZ and the 25 independent preparations of NPCP - BG . 
nanoparticle are administered at the same time . In another FIG . 6 illustrates suppression of MGMT by plotting 
embodiment , TMZ is administered before administration of percent cell survival as a function TMZ concentration with 
the nanoparticle . In a further embodiment , TMZ is admin and without BG . Suppression of MGMT activity with 
istered after administration of the nanoparticle . In certain NPCP - BG increases TMZ cell killing of the GBM line 
embodiments , the brain cancer is a TMZ - resistant brain 30 SF767 . Survival of SF767 cells treated with TMZ alone ( No 
cancer . In certain embodiments , the brain cancer is glioblas BG ) , or exposed to 20 uM BG ( closed circle ) or NPCP - BG 
toma multiforme . containing 20 UM BG ( open circles ) for 2 hr prior to 24 hr 
exposure to TMZ was determined by a clonogenic colony 
DESCRIPTION OF THE DRAWINGS forming assay . The inset displayed at a finer scale reveals the 
35 comparable effect of BG and NPCP - BG on cell killing . 
The patent or application file contains at least one drawing FIGS . 7A - 7F illustrate serum and organ biodistribution 
executed in color . Copies of this patent or patent application profile of NPCP - BG - CTX in wild type mice . FIG . 7A 
publication with color drawing ( s ) will be provided by the compares measured fluorescence intensity of nanoparticles 
Office upon request and payment of the necessary fee . in serum over time . FIG . 7B illustrates serum half - life of 
The foregoing aspects and many of the attendant advan - 40 NPCP - BG - CTX determined using fluorescence measure 
tages of this invention will become more readily appreciated ments . Each data point represents the mean fluorescence 
as the same become better understood by reference to the intensity integrated above the baseline . The curve indicates 
following detailed description , when taken in conjunction an exponential decay curve fit to the data ( n = 3 mice per time 
with the accompanying drawings . point ) . FIG . 7C shows fluorescence images of 12 - micron 
FIGS . 1A - 1D schematically illustrate the preparation of a 45 sections of various organs five days post injection obtained 
representative nanoparticle of the invention : NPCP - BG . using the Odyssey imaging system . The spectrum gradient 
FIG . 1A is a schematic illustration of functionalized NPCP bar corresponds to relative fluorescent level . ( Top row , from 
BG . FIG . 1B illustrates crosslinking of NPCP coating left to right : liver , spleen , and kidney . Bottom row from left 
through intracellular reducible disulfide linkages . FIG . 1C to right : lung , heart , and brain ) . The spectrum gradient bar 
illustrates activation of BG by bromination and subsequent 50 corresponds to the relative fluorescence intensity unit p / sec / 
reaction with amines on the chitosan backbone . FIG . 1D cm2 / srx10 ' . FIG . 7D is a quantitative representation of the 
illustrates crosslinking of NPCP and further modification biodistribution of NPCP - BG - CTX in liver , spleen , kidney , 
with BG to produce NPCP - BG . lung , heart , and brain . FIGS . 7E and 7F are fluorescence 
FIGS . 2A - 2D illustrates physicochemical properties of a images from a fluorescence - based BBB permeability assay . 
representative nanoparticle of the invention : NPCP - BG - 55 Shown are representative images of brains of wild - type mice 
CTX . FIG . 2A illustrates intensity - based hydrodynamic size receiving no - injection or tail vein injections of NPCP - BG 
distribution of NPCP - BG - CTX in 20 mM HEPES , PH 7 . 4 as CTX . The mice were sacrificed at 3 hours after treatment . 
determined by DLS . FIG . 2B illustrates volume - based FIG . 7E are fluorescence images of 12 - micron sections of 
hydrodynamic size distribution of NPCP - BG - CTX in 20 mice brain and 100x dilution of blood in 96 well plate 
mM HEPES , PH 7 . 4 as determined by DLS . FIG . 2C 60 scanned using the Odyssey imaging system . FIG . 7F shows 
compares NPCP - BG - CTX stability in biological fluid a histological examination of nanoparticle permeability 
( DMEM containing 10 % FBS ) over time . FIG . 2D illustrates across the BBB . Cell nuclei ( blue ; DAPI ) and endothelial 
zeta potential distribution of NPCP - BG - CTX in 20 mM cells ( green ; FITC - PECAM - 1 ) were stained to visualize the 
HEPES , PH 7 . 4 . localization of nanoparticles ( red ) within the brain tissue . 
FIGS . 3A and 3B illustrate environment sensitive release 65 The scale bar in the confocal images corresponds to 20 um . 
profile of BG from a representative nanoparticle of the FIGS . 8A - 8D illustrate the pharmacological evaluation of 
invention : NPCP - BG - CTX . FIG . 3A is a Coomassie blue a representative nanoparticle of the invention : NPCP - BG 
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CTX . FIG . 8A illustrates representative H & E stained tissue O? - benzylguanine or coating components that include 
sections of mouse liver , kidney , spleen , and cerebellum 0 - benzylguanine . In certain embodiments , the number of 
obtained from PBS injected animals and from those injected O? - benzylguanine moieties / nanoparticle is from about 50 to 
with NPCP - BG - CTX . Scale bar corresponds to 150 um . about 2000 . In other embodiments , the number of 06 - ben 
FIG . 8B shows the assessment of toxic effects of NPCP - 5 zylguanine moieties / nanoparticle is from about 100 to about 
BG - CTX on liver . AST and ALT levels of mice receiving 500 . In one embodiment , the number of O - benzylguanine 
NPCP - BG - CTX or PBS injection were measured five days moieties / nanoparticle is from about 150 . 
after administration ( mean - standard deviation of the mean , The crosslinked copolymer forms a coating on the core 
n = 3 mice per treatment ) . FIGS . 8C and 8D illustrates the surface . The copolymer is anchored to the core surface ( e . g . , 
evaluation of bone marrow toxicity in response to co - 10 oxide surface ) by interactions between the core surface and 
administration of BG and TMZ . FIG . 8C compares white the amine and hydroxyl groups on the copolymer ' s chitosan 
blood cell counts obtained from wild type mice 5 days post backbone . It is believed that the coating is a multi - layered 
treatment with PBS , NPCP - BG - CTX / TMZ , or BG / TMZ mesh that encapsulates the core . 
FIG . 8D compares platelet counts obtained from wild - type As used herein , the term " coating ” refers to the cross 
mice 5 days post treatment with PBS , NPCP - BG - CTX / 15 linked copolymer comprising a chitosan and a poly ( ethylene 
TMZ , or BG / TMZ . oxide ) oligomer associated with the surface of the nanopar 
ticle core . In certain embodiments , the core is substantially 
DETAILED DESCRIPTION OF THE surrounded by the copolymer ( i . e . , the core is coated with 
INVENTION the copolymer ) . The copolymer is directly associated ( e . g . , 
20 covalently or electrostatic interaction to the core surface . 
The present invention provides a nanoparticle having a The copolymer is not coupled to the core surface through 
crosslinked chitosan - polyethylene oxide oligomer copoly - one or more other materials ( e . g . , a protein , peptide , or 
mer coating to which O? - benzylguanine is covalently nucleic acid ) . In the nanoparticle of the invention , there are 
coupled . The crosslinked chitosan - polyethylene oxide oli no layers intermediate the core surface and the copolymer . 
gomer copolymer coating includes glutathione - sensitive 25 The coating of the nanoparticle is formed from a copo 
crosslinks that cause the coating to undergo degradation in lymer comprising a chitosan and a poly ( ethylene oxide ) 
glutathione - containing environments to deliver O° - benzyl - oligomer . In one embodiment , the copolymer is a graft 
guanine or coating components that include O - benzylgua - copolymer having a chitosan backbone and pendant poly 
nine effective to inhibit 0° - methylguanine - DNA methyl - ( ethylene oxide ) oligomer side chains . 
transferase ( MGMT ) and treat brain cancers that exhibit 30 Chitosan is a linear polysaccharide composed of ran 
increased expression of MGMT and to treat those brain domly distributed B - ( 1 - 4 ) - linked D - glucosamine ( deacety 
cancers ( e . g . , TMZ - resistant brain cancers ) . lated unit ) and N - acetyl - D - glucosamine ( acetylated unit ) . 
In certain embodiments , the nanoparticle has a core that Suitable chitosans useful in making the copolymers useful in 
includes a material that imparts magnetic resonance imaging the invention have a molecular weight ( weight average , 
activity to the particle . The nanoparticle can further include 35 Mw ) of from about 0 . 3 to about 50 kDa . In certain embodi 
one or more of a targeting agent to target the nanoparticle to ments , the chitosan has a molecular weight of from about 0 . 5 
a site of interest , and a diagnostic agent that allows for to about 15 kDa . In one embodiment , the chitosan has a 
imaging of the particle . The targeting and diagnostic agents molecular weight of about 10 kDa . Suitable chitosans 
can be coupled to the particle ' s copolymer coating . Methods include oxidatively degraded chitosans prepared from com 
for making and using the nanoparticles are also provided . 40 mercially available chitosan . 
Nanoparticle The copolymer also includes a plurality of poly ( ethylene 
In one aspect , the invention provides a functional nano - oxide ) oligomers . In one embodiment , poly ( ethylene oxide ) 
particle . oligomers are grafted to the chitosan ' s backbone to provide 
The nanoparticle has a core having a surface and com a copolymer having pendant poly ( ethylene oxide ) oligomer 
prising a core material , a coating on the surface of the core , 45 side chains . 
and Oº - benzylguanine covalently coupled to the coating . Suitable poly ( ethylene oxide ) oligomers include poly 
The coating comprises a crosslinked copolymer comprising ( ethylene oxides ) ( PEO or PEG ) and poly ( ethylene oxide ) 
a chitosan and a poly ( ethylene oxide ) oligomer . copolymers such as block copolymers that include poly 
The crosslinked copolymer comprises crosslinks that are ( ethylene oxide ) and poly ( propylene oxide ) ( e . g . , PEO - PPO 
glutathione - sensitive crosslinks . The crosslinks and the 50 and PEO - PPO - PEO ) . In one embodiment , the poly ( ethylene 
crosslinked copolymer coating undergo degradation in glu - oxide ) oligomer is a poly ( ethylene oxide ) . In certain 
tathione - containing environments . The greater the concen - embodiments , poly ( ethylene oxide ) oligomer has a molecu 
tration of glutathione in the environment , the more rapidly lar weight ( weight average , Mw ) of from about 0 . 3 to about 
and effectively the crosslinks and crosslinked copolymer 40 kDa . In others embodiments , the poly ( ethylene oxide ) 
coating are degraded . Degradation of the crosslinks and 55 oligomer has a molecular weight of from about 1 . 0 to about 
crosslinked copolymer coating results in delivery of O? - ben - 10 kDa . In certain embodiments , the poly ( ethylene oxide ) 
zylguanine or coating components that include O - benzyl - oligomer has a molecular weight of about 2 kDa . 
guanine that are effective to inhibit Oº - methylguanine - DNA Representative chitosan - poly ( ethylene oxide ) oligomer 
methyltransferase ( MGMT ) and treat brain cancers that copolymers include from about 2 to about 80 weight percent 
exhibit increased expression of MGMT and to treat those 60 poly ( ethylene oxide ) oligomer . In one embodiment , the 
brain cancers . Representative crosslinks useful in the nano - copolymer includes from about 5 to about 25 weight percent 
particle of the invention include disulfide crosslinks . poly ( ethylene oxide ) oligomer . 
As noted above , the nanoparticle includes O? - benzylgua - Representative chitosan - poly ( ethylene oxide ) oligomer 
nine ( e . g . , Oº - benzylguanine moieties ) covalently coupled graft copolymers have a degree of poly ( ethylene oxide ) 
to the nanoparticle coating that further includes glutathione - 65 oligomer substitution of from about 0 . 01 to about 0 . 5 . In 
sensitive crosslinks . Degradation of the coating in gluta - certain embodiments , the graft copolymers have a degree of 
thione - containing environments results in delivery of poly ( ethylene oxide ) oligomer substitution from about 0 . 01 
US 9 , 784 , 730 B2 
to about 0 . 2 . As used herein , the term “ degree of substitu - In certain embodiments , the nanoparticles of the invention 
tion ” or “ DS ” refers to the fraction of glucosamine repeating further include one or more other agents . Thus , in other 
units in the chitosan that are substituted with a poly ( ethylene embodiments , the nanoparticles of the invention further 
oxide ) oligomer . For DS = 1 . 0 , 100 % of the glucosamine include one or more of a targeting agent to target the 
units are substituted with the poly ( ethylene oxide ) oligomer . 5 nanoparticle to a site of interest , and / or a diagnostic agent 
The phrase “ core having a surface and comprising a core that allows for imaging of the particle . 
material ” refers to a solid nanoparticle . The nanoparticle Targeting Agents . 
core is not hollow ( e . g . , not a solid shell encapsulating a Suitable targeting agents include compounds and mol 
void ) . The core material can impart functional properties to ecules that direct the nanoparticle to the site of interest . 
the nanoparticle ( e . g . , magnetic properties ) . The core mate - " Suitable targeting agents include tumor targeting agents ( i . e . , 
rial is not a polymeric material ( e . g . , the nanoparticle is not brain cancer tumors ) such as ligands that specifically bind to 
a polymer nanoparticle or a polymeric nanosphere ) . As used tumor cell surface receptors . 
herein the term “ polymeric material ” refers to an organic Representative targeting agents include small molecules , 
polymer material ( e . g . , poly ( glycidyl methacrylate ) , poly 16 peptides , proteins ( e . g . , fusion protein , antibody or func 
( styrene ) , poly ( alkylacrylate ) ) . The core ' s surface defines tional fragment thereof ) , aptamers , and nucleic acids . Rep 
the core ' s outermost surface . In certain embodiments , the resentative small molecule targeting agents include biotin , 
nanoparticle core is a solid core comprising a material folic acid , and methotrexate ( folate receptors ) , non - peptidic 
having magnetic resonance imaging activity ( e . g . , iron RGD mimetics , vitamins , and hormones . Representative 
oxide ) . 20 peptide targeting agents include RGD ( avß3 integrin ) , chlo 
The nanoparticle includes a core material . For magnetic rotoxin ( MMP2 ) , and VHPNKK ( endothelial vascular adhe 
resonance imaging applications , the core material is a mate - sion molecules ) . Representative protein targeting agents 
rial having magnetic resonance imaging activity ( e . g . , the include antibodies against the surface receptors of tumor 
material is paramagnetic ) . In certain embodiments , the core cells , such as monoclonal antibody A7 ( colorectal carci 
material is a magnetic material . In other embodiments , the 25 noma ) , herceptin ( Her2 / ner ) , rituxan ( CD20 antigen ) , IFS 
core material is a semiconductor material . Representative ( anti - CD20 ) , and CC49 ( anti - TAG - 72 ) , and ligands such as 
core materials include ferrous oxide , ferric oxide , silicon annexin V ( phosphatidylserine ) and transferrin ( transferrin 
oxide , polycrystalline silicon oxide , silicon nitride , alumi receptor ) . Representative aptamer targeting agents include 
num oxide , germanium oxide , zinc selenide , tin dioxide , A10 RNA apatamer ( prostate - specific membrane antigen ) 
titanium , titanium dioxide , nickel titanium , indium tin oxide , 30 30 and Thrm - A and Thrm - B DNA aptamers ( human alpha 
gadolinium oxide , stainless steel , gold , and mixtures thereof . thrombin protein ) . Targets for the agents noted above are in 
The particle of the invention has nanoscale dimensions . parentheses . Representative nucleic acid targeting agents include DNAs ( e . g . , cDNA ) and RNAs ( e . g . , siRNA ) . Suitable particles have a physical size less than about 60 nm . 
In certain embodiments , the nanoparticles have a physical In certain embodiments , the targeting agent is chloro 35 toxin , or a variant or derivative thereof . Representative 
size from about 10 to about 50 nm . In other embodiments , chlorotoxin variants include variants in which one or more the nanoparticles have a physical size from about 10 to about of the polypeptides amino acid residues in native chloro 20 nm . As used herein , the term “ physical size ” refers the toxin is deleted , replaced with a conserved or non - conserved overall diameter of the nanoparticle , including core ( as amino acid , or modified such that the resulting variant determined by TEM ) and coating thickness . Suitable par par 40 retains 90 % or more of the targeting ability of native ticles have a mean core size of from about 2 to about 25 nm . chlorotoxin . Representative chlorotoxin variants useful in In certain embodiments , the nanoparticles have a mean core the invention include those described in U . S . Patent Appli size of about 7 nm . As used herein , the term “ mean core cation Publication No . 2007 / 0154965 , U . S . Patent Applica size ” refers to the core size determined by TEM . Suitable tion Publication No . 2010 / 0260686 , U . S . Patent Application particles have a hydrodynamic size less than about 300 nm . 
. 45 Publication No . 2013 / 0189367 , U . S . Patent Application In certain embodiments , the nanoparticles have a hydrody Publication No . 2013 / 0195760 , U . S . Patent Application namic size from about 30 to about 250 nm . In certain Publication No . 2013 / 0045163 , and WO 2013 / 003507 , each embodiments , the nanoparticles have a hydrodynamic size expressly incorporated herein by reference in its entirety . from about 30 to about 150 nm . In certain embodiments , the In certain embodiments , the number of chlorotoxins or nanoparticles have a hydrodynamic size of about 75 nm . As 50 variants or derivatives thereof / nanoparticle is from about 1 used herein , the term “ hydrodynamic size ” refers the radius to about 20 . In other embodiments , the number of chloro of a hard sphere that diffuses at the same rate as the particle toxins or variants or derivatives thereof / nanoparticle is from under examination as measured by DLS . The hydrodynamic about 2 to about 5 . In other embodiments , the number of radius is calculated using the particle diffusion coefficient chlorotoxins or variants or derivatives thereof / nanoparticle and the Stokes - Einstein equation given below , where k is the 55 is about 3 . Boltzmann constant , T is the temperature , and n is the In one embodiment , the invention provides a nanoparticle , dispersant viscosity : comprising : 
( a ) a core having a surface and comprising a core material ; 
( b ) a crosslinked chitosan - poly ( ethylene oxide ) oligomer 
60 copolymer coating on the surface ; ( c ) O® - benzylguanine is covalently coupled to the coating ; 
and 
A single exponential or Cumulant fit of the correlation ( d ) a targeting agent ( e . g . , chlorotoxin or variant or 
curve is the fitting procedure recommended by the Interna derivative thereof ) covalently coupled to the coating . 
tional Standards Organization ( ISO ) . The hydrodynamic 65 For this embodiment , suitable core materials include 
size extracted using this method is an intensity weighted magnetic materials and targeting agents are as described 
average called the Z average . above . 
RH = 6D 
nition 
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Diagnostic Agents . ( iii ) O? - benzylguanine is covalently coupled to the coat 
Suitable diagnostic agents include optical agents , such as ing ; and 
fluorescent agents that emit light in the visible and near - ( iv ) a targeting agent ( e . g . , chlorotoxin or variants or 
infrared ( e . g . , fluorescein and cyanine derivatives ) . Suitable derivatives thereof ) covalently coupled to the coating , 
fluorescent agents include fluorescein and derivatives , rho - 5 wherein the targeting agent has an affinity and specificity to 
damine and derivatives , and cyanines . Representative fluo - the cells or tissues of interest ; and 
rescent agents include fluorescein , OREGON GREEN 488 , ( b ) measuring the level of binding of the nanoparticle to 
ALEXA FLUOR 555 , ALEXA FLUOR 647 , ALEXA the cells or tissues of interest , wherein an elevated level of 
FLUOR 680 , Cy5 , Cy5 . 5 , and Cy7 . binding , relative to normal cells or tissues , is indicative of 
In one embodiment , the invention provides a nanoparticle , 10 binding to the cells or tissues of interest . In the method , the level of binding is measured by comprising : magnetic resonance imaging techniques . In a further ( a ) a core having a surface and comprising a core material ; embodiment of the above method , the nanoparticle further ( b ) a crosslinked chitosan - poly ( ethylene oxide ) oligomer includes a diagnostic agent ( e . g . , fluorescent agent ) . In this copolymer coating on the surface ; 15 embodiment , the level of binding can be measured by ( c ) O? - benzylguanine is covalently coupled to the coating ; magnetic resonance and / or fluorescence imaging tech 
and niques . The methods are applicable to detecting or imaging ( d ) a diagnostic agent ( e . g . , fluorescent agent ) covalently cells or tissues in vitro . The methods are also applicable to 
coupled to the coating . detecting or imaging cells or tissues in vivo . In such an 
For this embodiment , suitable core materials include 20 embodiment , the nanoparticles are administered to a subject 
magnetic materials and diagnostic agents are as described ( e . g . , warm - blooded animal , human ) by , for example , intra 
above . venous injection . 
In another embodiment , the invention provides a nano In a further embodiment , the invention provides a method 
particle , comprising : for treating a tissue , comprising contacting a tissue of 
( a ) a core having a surface and comprising a core material ; 25 interest with a nanoparticle of the invention having affinity 
( b ) a crosslinked chitosan - poly ( ethylene oxide ) oligomer and specificity for the tissue of interest , wherein the nano 
copolymer coating on the surface ; particle comprises ( c ) OC - benzylguanine is covalently coupled to the coating ; ( a ) a core comprising a core material and having a surface , 
( d ) a targeting agent ( e . g . , chlorotoxin or variant or ( b ) a coating on the surface of the core , the coating 
derivative thereof ) covalently coupled to the coating ; and 30 comprising a crosslinked copolymer comprising a chitosan 
( e ) a diagnostic agent ( e . g . , fluorescent agent ) . and a poly ( ethylene oxide ) oligomer , 
For this embodiment , suitable core materials include ( c ) Oº - benzylguanine is covalently coupled to the coating ; 
magnetic materials , targeting agents , and diagnostic agents and 
are as described above suitable targeting agents and diag . ( d ) a targeting agent ( e . g . , chlorotoxin or variants or 
nostic agents are as described above . 35 derivatives thereof ) covalently coupled to the copolymer , 
The preparation and characterization of representative wherein the targeting agent has an affinity and specificity to 
nanoparticles of the invention is described in Example 1 and the cells or tissues of interest . 
illustrated schematically in FIGS . 1A - 1D . The methods are applicable to treating tissues in vitro . 
Nanoparticle Compositions The methods are also applicable to treating tissues in vivo . 
In another aspect of the invention , a composition is 40 In this embodiment , the nanoparticles are administered to a 
provided that includes a nanoparticle of the invention and a subject ( e . g . , warm - blooded animal , human ) by , for 
carrier suitable for administration to a warm - blooded subject example , intravenous injection or nasal delivery . 
( e . g . , a human subject ) . Suitable carriers include those In the above methods , the cells or tissues of interest may 
suitable for intravenous injection ( e . g . , saline or dextrose ) be brain cancer cells or brain tissue , including cells and 
and nasal delivery . 45 tissues that exhibit increased expression of MGMT .
Methods for Using Nanoparticles In another embodiment , the invention provides a method 
In other aspects , the invention provides methods for using for inhibiting O? - methylguanine - DNA methyltransferase 
the nanoparticles of the invention . The methods include ( MGMT ) in a subject . In the method , a nanoparticle of the 
imaging methods such as magnetic resonance imaging when invention is administered to a subject ( e . g . , warm - blooded 
the core has magnetic resonance activity , and optical imag - 50 animal , human ) . 
ing when the nanoparticle includes a fluorescent agent . The In a further embodiment , the invention provides a method 
nanoparticles of the invention can also be used for O - ben - for introducing O? - benzyguanine into a cell . In the method , 
zyguanine delivery . For nanoparticles of the invention that a cell is contacted with a nanoparticle of the invention . In 
include targeting agents , imaging of and drug delivery to certain embodiments , the cell is a brain cancer cell , such as 
target sites of interest are provided . 55 a brain cancer cell that exhibits increased expression of 
In one embodiment , the invention provides a method for MGMT . 
detecting ( or imaging ) cells or tissues by magnetic reso - The invention also provides methods of treatment . In each 
nance imaging , comprising : of these methods of treatment , a therapeutically effective 
( a ) contacting cells or tissues of interest with a nanopar - amount of a nanoparticle of the invention is administered to 
ticle of the invention having affinity and specificity for the 60 a subject in need thereof . As used herein , the term “ thera 
cells or tissues of interest , wherein the nanoparticle com - peutically effective amount ” refers to an amount effective , at 
prises dosages and for periods of time necessary , to achieve the 
( i ) a core comprising a magnetic material and having a desired therapeutic result , such as tumor size reduction . A 
surface , therapeutically effective amount may vary according to 
( ii ) a coating on the surface of the core , the coating 65 factors such as the disease state , age , sex , and weight of the 
comprising a crosslinked copolymer comprising a chitosan subject , and the ability to elicit a desired response in the 
and a poly ( ethylene oxide ) oligomer , subject . Dosage regimens can be adjusted to provide the 
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optimum therapeutic response . A therapeutically effective BG delivery contains a superparamagnetic iron oxide core 
amount is also one in which any toxic or detrimental effects surrounded by a redox responsive biopolymer shell of PEG 
are outweighed by the therapeutically beneficial effects . and chitosan conjugated to tumor - targeting CTX . The safety , 
Dosage values can vary with the severity of the condition to BG intracellular trafficking , reduction of MGMT activity , 
be alleviated . For any particular subject , specific dosage 5 potentiation of TMZ cytotoxicity in GBM cells , biodistri 
regimens can be adjusted over time according to the indi bution , and toxicity of these NPs were evaluated and com 
vidual need and the professional judgment of the person pared against free BG . The BG - loaded NP formulation can 
administering or supervising the administration of the com be integrated into the existing therapeutic protocol for GBM positions . management and offers the potential to significantly improve In one embodiment , the invention provides a method for 10 the prognosis of GBM patients . treating a disease or condition treatable by inhibiting Formulation and Characterization of Nanoparticles O ' - methylguanine - DNA methyltransferase ( MGMT ) . Dis 
ease and conditions treatable by inhibiting MGMT include FIGS . 1A - 1D show the scheme for the synthesis of representative nanoparticles of the invention : crosslinked brain cancers , such as brain cancers that exhibit increase 
expression of MGMT . chitosan - grafted - PEG ( CP ) copolymer coated nanoparticles 
In another embodiment , the invention provides a method ( NPCP ) functionalized with BG ( NPCP - BG ) . The NPCP 
of treating brain cancers . Brain cancers that are treatable by consists of a 7 nm iron oxide core coated with CP ( FIG . 1A ) . 
the method include the brain cancers that are known to Reactive sulfhydryl groups were then introduced to the CP 
exhibit increased expression of MGMT , such as glioblas shell by reaction of 2 - iminothiolane to amine groups of 
toma multiforme . Because increased expression of MGMT 20 chitosan ( FIG . 1B ) . The sulfhydryl groups then oxidized and 
is responsible for TMZ - resistance , in certain embodiments formed disulfide bridges producing a redox - sensitive cross 
the treatable brain cancer is a TMZ - resistant brain cancer . linked polymer shell ( i . e . , coating ) . A 5 : 1 weight ratio of 
It will be appreciated that in the above methods of 2 - iminothiolane to iron was determined to be optimal for 
treatment , additional chemotherapeutic agents known in the stability of NPCP . BG was then activated with N - bromo 
art to treat brain cancers ( e . g . , TMZ ) can be administered in 25 succinimide rendering it amine reactive ( FIG . 1C ) . The 
combination with the nanoparticles of the invention . formation of brominated BG was confirmed by tandem In a further embodiment , the invention provides a com In a further , a om - liquid chromatography - mass spectrometry ( LC - MS ) . NPCP bination therapy for treating brain cancers . In the method , a was then reacted with the brominated BG to produce NPCP therapeutically effective amount of TMZ and a therapeuti BG ( FIG . 1D ) . The BG loaded nanoparticles were readily 
cally effective amount of a nanoparticle of the invention is 30 soluble in PBS and cell culture media without the need of administered to a subject in need thereof . In certain embodi addition of excipients . 
ments , TMZ and the nanoparticle are administered at the The hydrodynamic size and zeta potential of nanoparticles same time . In certain embodiments , TMZ is administered can drastically influence their in vivo functionality , clear before administration of the nanoparticle . In other embodi 
ments . TMZ is administered after administration of the 35 ance , and overall safety . The intensity and volume based 
nanoparticle . Brain cancers that are treatable by the method hydrodynamic sizes of NPCP - BG - CTX in 20 mM HEPES , 
include the brain cancers that are known to be treatable by pH 7 . 4 was measured by dynamic light scattering ( DLS ) 
administering TMZ , and brain cancers that exhibit increased ( FIGS . 2A and 2B ) . The Z - average size of NPCP - BG - CTX 
expression of MGMT . Because increased expression of was 76 nm in HEPES and remained stable in biological fluid 
MGMT is responsible for TMZ - resistance , in certain 40 ( DMEM with 10 % FBS ) for over 10 days ( FIG . 2C ) . 
embodiments the treatable brain cancer is a TMZ - resistant Notably , the hydrodynamic size distributions for the NP 
brain cancer . remained appropriate for in vivo navigation and evasion of 
The following is a description of specific nanoparticles of rapid clearance by the reticuloendothelial system ( 5 
the invention and methods for making and using the nano nm < d < 200 nm ) . Additionally , a strong positive surface 
particles . 45 charge can lead to non - specific interactions with negatively 
As noted above , glioblastoma multiforme ( GBM ) is a charged cell membranes , whereas a strong negative surface 
highly aggressive brain tumor and remains the most deadly charge can lead to non - specific interactions with the posi 
malignancy despite aggressive neurosurgery followed by tively charged extracellular matrix . The average zeta poten 
radiochemotherapy . Temozolomide ( TMZ ) , a DNA methyl - tial of NPCP - BG - CTX was measured to be near neutral at 
ating agent , has become the standard of care in post - 50 + 4 mV ( FIG . 2D ) . 
operative radiochemotherapy of GBMs as it increases Table 1 summarizes physicochemical properties of 
median survival from 12 to 15 months . However , the effects NPCP - BG - CTX . Using UV / Vis spectroscopy the number of 
of TMZ are greatly lessened in patients that express high BG molecules per NP was estimated at 150 molecules per 
levels of the DNA repair protein O? - methylguanine - DNA NP . Furthermore , using a gel electrophoresis assay the 
methyltransferase ( MGMT ) . Inhibition of MGMT using 55 numbers of CTX peptides per NP were found to be approxi 
O? - benzylguanine ( BG ) has shown promise in these mately three peptides per NP . 
patients , but its clinical use is hindered by poor pharma 
cokinetics causing unacceptable toxicity . TABLE 1 
In one embodiment , the present invention provides a 
Physicochemical properties of NPCP - BG - CTX . multifunctional , BBB - permeating , NP formulation carrying 60 – 
a targeting ligand specific to GBMs and loaded with a BG Hydro - Poly Zeta 
chemotherapeutic payload that represents an effective and Core dynamic Disper - Volume Poten - Mol CTX 
less toxic treatment strategy . The nanoparticles of the inven Size Size sion based ecules / Molecules / 
tion effectively reformulates BG in combination with a ( nm ) ( nm ) Index size ( nm ) ( mV ) NP N P 
theranostic nanoparticle platform to improve its intracellular 65 7 . 5 76 0 . 16 49 + 4 150 3 
delivery to GBM cells while minimizing its localization to 
healthy tissue . In one embodiment , the NP formulation for 
BG 
tial 
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Redox - Responsive BG Release NPCP - BG Inhibition of MGMT and Potentiation of TMZ 
A challenge in developing drug carrier NP formulations is Cytotoxicity in Human GBM Cells 
ensuring rapid and effective intracellular release of drugs MGMT is the sole repair activity that removes Oº - meth 
while minimizing release in the blood . Several strategies ylguanine ( O® - meG ) adducts from DNA in human cells and 
have been evaluated to create NP formulations that selec - 5 plays an important role in GBM resistance to TMZ both in 
tively respond to environmental stimuli such as temperature , vitro and in vivo . Suppressing DNA repair is a promising pH , ionic strength , redox potential , and electrical or mag strategy for improving TMZ - based therapies . FIG . 5 shows 
netic fields . Among them , redox responsive NPs are most the effect of free BG and NPCP - BG treatments on MGMT attractive as cells regulate the reducing potential in their activity in SF767 cells . In this experiment , MGMT activity environment both intracellularly and extracellularly through 10 was assayed in untreated cells , cells incubated with 20 uM the expression and secretion of reducing enzymes such as free BG for 2 hr , and cells treated for either 2 hr or 24 hr with glutathione . These enzymes are known to be present in the 
cytoplasm at 1000 - fold higher levels than those found in the NPCP - BG equivalent to 5 uM , 10 uM or 20 UM BG . 
blood . Untreated cells had an activity of 39 fmol / 10° cells or about 
To determine the redox responsive properties of the 23 , 500 MGMT molecules / cell . All treatment conditions 
nanoparticles of the invention . NPCP - BG - CTX was incu - 15 were normalized as a percent MGMT activity of untreated 
bated in conditions mimicking blood conditions ( BC envi - SF767 cells . Exposure to free BG reduced the activity by 
ronment : PBS pH 7 . 4 ) and intracellular conditions ( IC about 28 - fold ( about 3 . 6 % of untreated activity ) . Impor 
environment : acetate buffer pH 5 and 100 mM glutathione ) tantly , incubation with NPCP - BG for 2 hr also diminished 
to examine drug release under conditions likely encountered MGMT activity in a dose dependent fashion , achieving a 
following NP tumor uptake and intracellular sequestration . 20 greater than 50 - fold reduction in activity 24 hr after a single 
Gel electrophoresis was used to monitor biodegradation of exposure to NPCP - BG with 5 uM equivalent BG concen 
the CP coating in response to BC IC environments ( FIG . tration . In addition , higher dosages of NPCP - BG ( 10 uM and 
3A ) . The IC environment resulted in more degradation than 20 UM BG equivalency ) demonstrated about 67 - fold and 
the BC environment . BG release was quantitatively moni - about 90 - fold reduction in activity . These results demon 
tored using a fluorescence assay ( FIG . 3B ) . BG released 25 strate that NP - conjugated BG produces near total ablation of 
rapidly under conditions mimicking intracellular environ - MGMT activity in a human GBM cell line . While the 
ments reaching maximum BG release at 1 hr . However , inhibition of MGMT in vitro was similar for NPCP - BG and 
under conditions mimicking blood , maximum BG release free drug , the NP formulated BG presents advantages in 
was not achieved until 24 hrs . In vivo , the majority of vivo , due to its improved blood half - life and favorable 
NPCP - BG - CTX would be cleared from the blood by 24 hrs , 30 biodistribution . 
minimizing off target accumulation of free BG . The SF767 cells are noted for their pronounced resistance to 
improvement in BG release under IC conditions demon TMZ ( LDs , about 600 uM mediated in large part by 
strates that controlled intracellular BG drug release can be MGMT . The effect of suppression of MGMT activity by 
achieved using this NP formulation . NPCP - BG on TMZ - mediated reduction in clonogenic sur 
Internalization of NPCP - BG - CTX by Human GBM Cells 35 vival of SF767 is illustrated in FIG . 6 . Cells were exposed 
In Vitro to NPCP - BG equivalent to 20 uM free drug for 2 hr followed 
To efficiently deliver BG in vivo , NPs must be equipped by incubation with TMZ for 24 hr in the presence of 
with ligands that bind to tumor cells with high specificity inhibitor . Controls were treated either with 20 uM free BG 
and avidity . CTX , a small peptide of scorpion venom that or with an equivalent volume of DMSO . NPCP - BG reduced 
binds to MMP2 in cell membrane lipid rafts , has high 40 the resistance by about 35 - fold ( LDs , about 23 uM ) , a 
specificity and avidity for GBM which overexpresses potentiation of cytotoxicity comparable that produced by 
MMP2 , but not normal brain tissue . CTX - conjugated NPs free BG ( LD50 about 15 uM ) . These results demonstrate that 
are efficiently taken up by endocytosis in rodent glioma NPCP - BG mediated suppression of MGMT is accompanied 
cells . Unlike other ligands , which only target certain types of by greater sensitivity to TMZ in human GBM cells . 
brain tumors , CTX targets the majority of brain tumors 45 NPCP - BG - Cy5 . 5 - CTX In Vivo Serum Half - Life , Biodis 
examined ( 74 out of 79 ) . In addition , CTX facilitates BBB tribution , and BBB Permeability 
permeation via receptor - mediated transcytosis through ves - For assessment of serum half - life , a reproducible , quan 
sel endothelial cells . titative assay was used that utilized the NIRF dye , Cy5 . 5 , 
Visual confirmation of NP internalization and BG deliv - which was incorporated into the nanoparticle . Mice were 
ery was established by confocal microscopy . Images ( FIG . 50 injected through tail vein with 200 uL of 1 mg / ml NPCP 
4 ) were obtained from SF767 cells treated with NPCP - BG - Cy5 . 5 - CTX ( n = 3 for each time point ) and blood was 
AF647 - CTX ( NPs labeled with fluorophore ) , BG - AF647 collected from mice at 1 , 8 , and 24 , hours . Blood was ( fluorophore labeled BG ) , and NPCP - ( BG - AF647 ) - CTX centrifuged and the plasma was collected for analysis . The 
( NPs carrying fluorophore labeled BG ) . In all images ( FIG . blood plasma was added to a 96 well clear bottom plate and 
4 ) , cell nuclei were stained with DAPI ( blue ) and mem - 55 scanned using the Odyssey scanner . Exponential decay 
branes with WGA - 555 ( green ) . Treatments with the formu - analysis of the fluorescent signal from NPCP - BG - Cy5 . 5 
lations were administered at a concentration of 50 uM of BG CTX over time revealed an elimination half - life of 5 hours 
or its NP equivalence . In the top panel , NPCP - AF647 - CTX ( FIGS . 7A and 7B ) . This is significantly longer than the 1 . 2 
( red , third column ) can be visualized in the treated cells . The hours reported in literature for BG evaluated in rodent 
overlay images ( fourth column ) reveal that the delivered 60 models . 
NPCP - AF647 - CTX formulation is predominantly localized The biodistribution of the mice receiving NPCP - BG 
in the perinuclear region of cells , a common observation Cy5 . 5 - CTX was determined by ex vivo NIRF signal quan 
with similar NPs . The middle and lower panels show the tification of excised tissues ( brain , liver , spleen , kidney , 
BG - AF647 to be localized in the nucleus even with NPCP - heart and lung ) ( FIGS . 7C and 7D ) . Wild type mice were ( BG - AF647 ) - CTX delivery , where NPs were observed in 65 chosen for their intact immune system . Mice were injected 
the perinuclear region . This observation suggests the proper ( n = 3 ) through the tail vein with 200 ul of 1 mg / ml of 
release and trafficking of BG within cells . NPCP - BG - Cy5 . 5 - CTX . Whole organs were removed at 120 
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hours after injection , frozen in OCT , and then sliced in 12 Combined , these findings suggest that NPCP - BG - CTX 
um sections and mounted on glass slides . The slides were produced less myelosuppression and were more tolerable 
scanned on the Odyssey NIR scanner and images were when combined with TMZ as compared to free BG . The 
obtained using the 700 nm channel ( FIG . 7C ) . The measured decrease in myelosuppression is likely due to the favorable 
fluorescence intensities were then plotted to determine a 5 biodistribution of these NPs . 
biodistribution profile ( FIG . 7D ) . No marked nanoprobe In summary , in certain embodiments , the invention pro 
accumulation was observed in brain , heart , and lung tissue . vides GBM targeted NPs carrying a BG payload . These NPs 
Conversely , significant accumulation of the NPCP - BG - had excellent physicochemical properties and demonstrated 
Cy5 . 5 - CTX was observed in clearance organs including a redox - responsive drug release profile . In vitro evaluation 
liver , spleen , and kidney . 10 of NPCP - BG - CTX demonstrated proper release and traf 
To evaluate BBB permeability of NPCP - BG - CTX , analy - ficking of BG within human GBM cells . NPCP - BG treated 
sis was performed on mouse brain sections three hours after human GBM cells showed near ablation of MGMT activity 
NP administration ( FIG . 7 ) . Gross examination was first similar to free BG treated cells . In addition , NPCP - BG 
performed on 12 um thick brain sections using Odyssey mediated suppression of MGMT was accompanied by sig 
scanner assays described above to monitor biodistribution 15 nificantly greater sensitivity to TMZ in human GBM cells . 
( FIG . 7E ) . Images obtained from three mice show distribu - Blood half - life and BBB permeability studies showed 
tion of nanoparticles throughout the entire brain with mark NPCP - BG - CTX persisted longer in blood than free BG and 
edly higher intensities noticeable in blood vessels . As a successfully permeated the BBB . Pharmacological evalua 
control , brain tissue from mice receiving no injection is also tions showed there was no difference in liver toxicity 
displayed to verify that the signal is not from tissue auto - 20 between saline injected and NP injected mice indicating the 
fluorescence . The extravasation of nanoparticles from blood innocuous toxicity profile of NPCP - BG - CTX . Furthermore , 
vessels was further confirmed through immunohistological co - treatment of wild type mice with NPCP - BG - CTX and 
analysis of mouse brain sections ( FIG . 7F ) . The presence of TMZ was much better tolerated than treatment with free BG 
fluorescent signal in the brain ' s extracellular matrix of combined with TMZ , which produced significant myelosup 
wild - type mice further supports the ability of these particles 25 pression . 
to escape the neural vasculature . The following examples are provided for the purpose of 
NPCP - BG - CTX Pharmacological Evaluation illustrating , not limiting , the invention . 
Tissue specific toxicity was examined through histologi 
cal analysis on various tissues ( kidney , spleen , liver , and EXAMPLE 
brain ) of mice injected with NPCP - BG - CTX to identify any 30 
signs of acute toxicity . Tissues were harvested from mice Example 1 
120 h after receiving nanoparticle injection , fixed in 10 % 
formalin , embedded in paraffin , sectioned , and stained with Materials . 
hematoxylin and eosin ( H & E ) . Tissue sections showed no All reagents were purchased from Sigma Aldrich ( St . 
evidence of toxicity , appearing similar to those observed in 35 Louis , Mo . ) unless otherwise specified . The heterobifunc 
the tissues from PBS injected control animals ( FIG . 8A ) . tional linker 2 - iminothiolane ( Traut ' s reagent ) was pur 
Because the accumulation of nanoparticles in liver have chased from Molecular Biosciences ( Boulder , Colo . ) . NHS 
been reported and shown with NPCP - BG - CTX , potential PEG12 - maleimide was purchased from Thermo Fisher 
toxicity of the accumulated NPs to liver was assessed by a Scientific ( Rockford , Ill . ) . Tissue culture reagents including 
hepatotoxicity assay . Serum aspartate aminotransferase 40 Dulbecco ' s modified Eagle medium ( DMEM ) and antibi 
( AST ) and alanine aminotransferase ( ALT ) levels were otic - antimycotic were purchased from Invitrogen ( Carlsbad , 
determined in mice injected with NPCP - BG or PBS ( FIG . Calif . ) . Fetal bovine serum ( FBS ) was purchased from 
8B ) . No marked elevation of AST and ALT levels was found Atlanta Biologicals ( Lawrenceville , Ga . ) . 
in mice receiving NPCP - BG - CTX compared to control mice NPCP Synthesis . 
receiving PBS injection , suggesting that NPs do not induce 45 Iron oxide nanoparticles coated with a copolymer of 
liver toxicity at the given dosage . chitosan - grafted - PEG were synthesized via a co - precipita 
Aconcern associated with combinational therapy of brain tion method as previously reported ( Veiseh et al . , Cancer 
tumors through co - administration of BG and TMZ is dose Res . 2009 , 69 , 6200 - 7 ) . Briefly , chitosan oligosaccharide 
limiting chemotherapy - induced bone marrow toxicity . In the ( 5 , 000 kDa ) was PEGylated with aldehyde - activated 
clinic , chemotherapy induced myelosuppression is detected 50 methoxy PEG , and monolabeled chitosan - grafted - PEG ( CP ) 
through blood work by the decrease in the number of white was purified using ion exchange chromatography . Pure CP 
blood cells ( neutropenia ) and platelets ( thrombocytopenia ) . ( 150 mg ) was mixed with iron chlorides ( 9 mg Fe2 + , 15 mg 
To monitor whether co - administration of TMZ with NPCP - Fe3 + ) in 2 . 18 mL of degassed DI water . A 14 . 5 M solution 
BG - CTX is more tolerable in mice compared to BG , the of sodium hydroxide was titrated in slowly at 40° C . until a 
influence of each formulation on white blood cell ( WBC ) 55 final pH of 10 . 5 was reached to ensure complete nucleation 
and platelets levels in peripheral blood ( FIGS . 8C and 8D ) of NPs . At this point , the synthesized NPCP were purified 
was evaluated . Mice were injected with NPCP - BG at a BG using size exclusion chromatography in S - 200 resin ( GE 
dose of 6 mg / kg followed two hours later by an injection of Healthcare , Piscataway , N . J . ) into 100 mM sodium bicar 
66 mg / kg TMZ and sacrificed 5 days later . Mice receiving bonate buffer , pH 8 . 0 containing 5 mM EDTA . NPCP was 
PBS and free BG injections were also included in our study 60 then thiolated using Traut ' s reagent ( 10 mg ) in 100 uL of 100 
as controls . Peripheral blood was collected through cardiac mM sodium bicarbonate , pH 8 . 0 , 5 mM EDTA . The reaction 
heart puncture . BG / TMZ produced almost complete knock - was maintained in the dark at room temperature for 1 hr . The 
down of WBC and platelet levels indicating substantial thiolated NPCP was purified using size exclusion chroma 
neutropenia and thrombocytopenia . Importantly , NPCP - BG - tography in S - 200 resin ( GE Healthcare , Piscataway , N . J . ) 
CTX / TMZ produced significantly lower degrees of WBC 65 into 100 mM sodium bicarbonate buffer , pH 8 . 5 without 
and platelet suppression compared to BG / TMZ treatments EDTA and subsequently aged overnight at 4° C . to promote 
indicating they do not accumulate in the bone marrow . disulfide formation . 
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NPCP - BG and NPCP - BG - CTX Synthesis . BG - 488 was conjugated to NPCP as described above to 
NPCP in 100 mM sodium bicarbonate buffer , pH 8 . 5 was produce ( NPCPX - ( BG - AF488 ) ) . NPCP - ( BG - AF488 ) ( 1 mg 
mixed with BG - Br ( prepared as described in Example 2 ) of Fe / ml ) were diluted into PBS at pH 7 . 4 and acetate buffer 
dissolved in dimethyl formamide ( DMF ) at a 5 : 1 weight at pH 5 . 0 containing 100 mM glutathione and incubated at 
ratio of iron to BG - Br . DMF volume was limited to 10 % of 5 37° C . for 0 , 1 , 8 , and 24 h . Free drug was separated from 
the total reaction volume . The reaction was maintained in NPCP - ( BG - AF488 ) using Amicon centrifuge filters ( 10 , 000 
the dark at room temperature for 24 hrs to produce NPCP - MW cutoff , Millipore ) . Free BG - AF488 content in the 
BG . 300 uL of the NPCP - BG reaction mixture was set aside filtrate was determined by fluorescence measurements . Per 
for evaluation of BG loading . The remaining NPCP - BG was cent BG released from NPCP - ( BG - AF488 ) was calculated 
purified using size exclusion chromatography in S - 200 resin 10 using the fluorescence of total amount of drug released over 
( GE Healthcare , Piscataway , N . J . ) into 100 mM sodium the 24 hour period . 
bicarbonate buffer , pH 8 . 0 containing 5 mM EDTA for Cell Culture . 
further conjugations of fluorophores and chlorotoxin ( CTX ) . SF767 , a human GBM cell line , ( ATCC , Manassas , Va . ) 
NPCP - BG ( 3 . 5 mg ) was reacted with 1 mg of Cy5 . 5 ( GE was maintained in Dulbecco ' s Modified Eagle Medium 
healthcare ) in 100 mM sodium bicarbonate buffer , pH 8 . 0 15 ( DMEM , Invitrogen , Carlsbad , Calif . ) supplemented with 
containing 5 mM EDTA for 1 hr at room temperature 10 % FBS ( Atlanta Biologicals , Lawrenceville , Ga . ) and 1 % 
protected from light and with gentle rocking . A 1 mg / mL antibiotic - antimycotic ( Invitrogen , Carlsbad , Calif . ) at 37° 
solution of CTX ( Alamone Labs , Jerusalem , Israel ) was C . and 5 % CO2 . 
prepared in thiolation buffer and reacted with 21T at a 1 . 2 : 1 Confocal Fluorescence Microscopy . 
molar ratio of 21T : CTX for 1 hour in the dark . Concurrently , 20 50 , 000 treated cells were plated on each of 24 mm glass 
NPCP - BG - Cy5 . 5 was reacted with SM ( PEG ) , ( Thermo cover slips and allowed to attach for 24 hrs . Cells were then 
Fisher Scientific , Waltham , Mass . ) at 216 ug of SM ( PEG ) washed with PBS and fixed in 4 % formaldehyde ( Poly 
12 / mg Fe3O4 in the dark with gentle rocking for 30 minutes . sciences Inc . , Warrington , Pa . ) for 30 min . Cells were then 
The SM ( PEG ) , modified NPCP - BG - Cy5 . 5 was then washed three times with PBS and membrane - stained with 
reacted with CTX - 21T at 1 ug CTX per 4 . 5 ug Fe for one 25 WGA - AF555 ( Invitrogen , Carlsbad , Calif . ) according to the 
hour in the dark to produce NPCP - BG - CTX . The resultant manufacturer ' s instructions . Cover slips were then mounted 
NP was purified using size exclusion chromatography in on microscope slides using Prolong Gold antifade solution 
S - 200 resin equilibrated with PBS , and stored at 4° C . ( Invitrogen , Carlsbad , Calif . ) containing DAPI for cell 
Evaluation of BG Loading . nuclei staining . Images were acquired on a LSM 510 Meta 
300 uL of the NPCP - BG reaction mixture was placed in 30 confocal fluorescence microscope ( Carl Zeiss Inc . , Peabody , 
a 3000 MW cut off Amicon Ultra centrifugal filter ( Milli Mass . ) with the appropriate filters . 
pore , Billerica , Mass . ) and centrifuged at 12 , 000 rcf for 10 MGMT Activity Assay . 
minutes . The flow through containing unreacted BG was The MGMT activities of protein extracts of human GBM 
collected and free BG was quantified by absorbance mea - SF767 cells were measured in a standard biochemical assay 
surements at 280 nm using a SpectraMax M2 microplate 35 that quantifies the transfer of radioactivity from a DNA 
reader ( Molecular Devices , Sunnyvale , Calif . ) and standard substrate containing [ methyl ’ H ] Oº - methylguanine ( specific 
curve of known BG concentrations . BG conjugated to NPs activity , 80 Ci / mmol ) to protein , as detailed previously 
was calculated by subtracting the amount of free BG from ( Silber et al . , Cancer Res 1998 , 58 , 1068 - 1073 ) . 2x106 
the total amount of BG in the reaction . SF767 cells were plated in 100 mm treated dishes and 
Nanoparticle Size and Zeta Potential Characterization . 40 incubated with 20 uM free BG for and 2 hr or 24 hr with 
Hydrodynamic size and zeta potential of NPCP - BG - CTX NPCP - BG equivalent to 5 UM , 10 uM or 20 uM BG in fully 
was analyzed at 100 ug / mL in 20 mM HEPES buffer ( pH supplemented media . After incubation , cells were washed 
7 . 4 ) using a DTS Zetasizer Nano ( Malvern Instruments , with PBS and collected and protein extracts were prepared . 
Worcestershire , UK ) . NPCP - BG - CTX stability in biological The protein extract supernatant was prepared by dissolution 
fluid was analyzed at 100 ug / mL in Dulbecco ' s Modified 45 of washed SF767 pellets of known cell number with non 
Eagle Medium ( DMEM , Invitrogen , Carlsbad , Calif . ) ionic detergents in the presence of 600 mM NaCl . Aliquots 
supplemented with 10 % FBS ( Atlanta Biologicals , Law of crude homogenate were saved for DNA determination by 
renceville , Ga . ) and 1 % antibiotic - antimycotic ( Invitrogen , the diphenylamine method that measures deoxyribose fol 
Carlsbad , Calif . ) . lowing degradation of DNA with heat and acid . Crude 
Evaluation of CTX Labeling . 50 homogenate was cleared by centrifugation at 10 , 000xg for 
To quantify the degree of CTX attachment to nanopar - 30 min . Activity , normalized to cell number using a con 
ticles , NPCP - BG - CTX was prepared as described above version factor of 6 pg DNA per cell , is fmol O? - methylgua 
except unbound CTX was not purified from the NPCP - BG - nine transferred per 10 cells . 
CTX reaction mixture using the S - 200 sephacryl resin . Free , Clonogenic Survival Assay . 
unreacted CTX was separated from the CTX conjugated to 55 Determination of proliferative survival of SF767 by clo 
NPs through SDS - PAGE and quantified using the Quantity nogenic assay was performed as described previously 
One software package and a standard curve of known ( Blank et al . , DNA Repair 2004 , 3 , 629 - 638 ) . Briefly , 6 - well 
concentrations of CTX . CTX conjugated to NPs was calcu plates inoculated with 2 mL of supplemented medium con 
lated by subtracting the amount of free CTX from the total taining 1000 to 2000 cells were incubated overnight at 37° 
amount of CTX in the reaction . 60 C . in 95 % / 5 % air / CO , to allow reattachment and resumption 
Drug Release . of proliferation . Cells were then incubated for 2 hrs with 
For this assay an Alexa Fluor 488 ( AF488 : Invitrogen , inhibitor - conjugated NP equivalent to 20 uM free BG prior 
Carlsbad , Calif . ) labeled version of BG was prepared . An to exposure to TMZ . Incubation was continued for 22 hr 
amine - modified version of BG ( BG - NH2 ) was purchased before changing cells to fresh , drug - free medium to allow 
from New England BioLabs Inc . ( Ipswich , Mass . ) and 65 formation of colonies 250 cells . Controls included cells 
modified with AF488 according to the manufacturer ' s treated with unconjugated NPs or with 20 uM free BG : 
instructions to produce AF 488 modified BG ( BG - AF488 ) . untreated controls received an equivalent volume of DMSO 
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solvent . Survival ( mean SD ) is the ratio of colony - forming ted to a veterinary pathology laboratory ( Phoenix Labora 
ability of treated cells to that of untreated cells . Cytotoxicity t ories , Everett , Wash . ) for third party analysis . 
was quantitated by linear regression analysis of plots of log 
surviving fraction v . TMZ dose to obtain the dose required Example 2 
to reduce survival to 50 % , LD50 . Survival was determined in 5 
4 separate experiments in which every dose was assayed in Preparation of Brominated Benzylguanine 
duplicate ( i . e . , 8 determinations per TMZ dose ) in order to 
achieve statistical significance . In this example , the preparation of brominated benzyl 
Serum Half - Life . guanine ( BG - Br ) is described . Bromination of benzylgua 
All animal studies were conducted in accordance with 10 nine ( BG ) at the C8 position was performed to covalently 
University of Washington ' s Institute of Animal Care and couple BG to NPCPx . 
Use Committee ( IACUC ) approved protocols as well as with BG ( 2 . 4 mg ) was dissolved in 500 uL methanol ( MeOH ) 
federal guidelines . C57BL6 wild type mice ( Charles River and mixed with N - bromosuccinimide ( 2 mg ) dissolved in 
Laboratories , Inc . ) were injected through the tail vein with 500 uL MeOH . The reaction was maintained in the dark at 
200 ul of 1 mg / ml nanoparticle ( n = 3 ) . At 1 , 8 , and 24 hours 15 room temperature for 24 hr to provide brominated BG 
after injection , blood was collected by retro - orbital eye bleed ( BG - Br ) . MeOH was removed under vacuum . 
or terminal heart puncture . Because of limitations on the A Hewlett Packard 1100 Liquid Chromatography ( LC ) 
amount of blood that can be drawn from each animal , no system ( Palo Alto , Calif . , USA ) , with autosampler , was 
animal was used for more than one time points . Blood coupled to a Bruker Esquire ion trap mass spectrometer 
samples were drawn from three independent mice for each 20 ( Billerica , Mass . , USA ) with electrospray ionization ( ESI ) 
time point and frozen at - 80° C . until analysis . Samples source . The benzylguanine / N - bromosuccinimide reaction 
were thawed at room temperature for 30 minutes prior to mixture was separated with an Agilent Zorbax narrow bore 
analysis . Whole blood was spun using a bench top centrifuge C18 column that was 100 mmx2 . 1 mm i . d . with 3 . 5 um 
for 5 minutes at 10 , 000 rpm to separate the plasma . 50 ml of particle size ( Agilent , Santa Clara , Calif . , USA ) . A binary 
plasma was then added to a 96 well clear bottom plate . The 25 mobile phase system of solvent A ( water with 5 % acetoni 
plate was scanned on the Odyssey NIR fluorescence imaging trile and 1 % acetic acid ) and solvent B ( acetonitrile with 1 % 
instrument ( LI - COR , Lincoln , Nebr . ) using the 700 nm acetic acid ) provided the best separation at 30° C . and a flow 
channel ( exc = 685 nm with hem = 705 nm ) to measure rate of 200 ul / min with the following gradient : B increased 
Cy5 . 5 fluorescence signals . from 0 % to 50 % over 15 min . followed by an increase to 
Biodistribution of Nanoparticles . 30 100 % B by 16 . 5 minutes . 1 ul of sample was injected onto 
Animals were injected via tail vein with 200 ul of 1 mg / ml the column . 
of nanoparticles . Three additional non - injected animals were Analytes were ionized for mass spectrometric detection 
included as controls . 48 hours after injection ( n = 3 ) the by positive ion ESI with the following conditions : spray 
animals were euthanized and tissues were dissected from 6 voltage , 3 kV ; drying gas temperature , 350° C . ; drying gas 
different organs : liver , spleen , kidney , lung , heart , and brain . 35 flow rate , 10 1 / min ; nebulizer , 30 psi ; capillary voltage , 4 
Tissues were then embedded in OCT and kept frozen at - 80 KV . MS data were collected in full scan mode over the mass 
C . until needed . The frozen tissues were sliced in 12 um range 50 - 2200 m / z with a scan resolution of 13 , 000 m / z / sec . 
thick sections and mounted onto glass slides . The tissue Ion optic voltages were as follows : skimmer 1 , 30 V ; 
sections were thawed at room temperature for 30 minutes skimmer 2 , 6 V ; octopole , 3 V ; octopole RF , 100 Vpp ; 
and the fluorescence intensity was measured using the 40 octopole A , 2 V ; lens 1 , - 5 V ; lens 2 , - 60 V . Bruker Daltonics 
Odyssey fluorescence scanner at a resolution of 21 mm . The Data Anlysis software , version 3 . 0 , was used for data acqui 
images were analyzed with the public domain ImageJ soft - sition and analysis . 
ware ( US National Institutes of Health , Bethesda , Md . ) . The Successful modification of BG was confirmed by tandem 
average fluorescence intensity was determined for each liquid chromatography - mass spectrometry ( LC - MS ) . The 
tissue type using the same threshold settings ( low threshold : 45 chromatographic peak at 13 . 1 min ( 242 m / z ) corresponds to 
400 , high threshold : 20 , 000 ) . Data are reported as the unmodified BG , whereas the peak at 16 . 2 min ( 321 - 323 m / z ) 
average channel fluorescence of the tissue , given as relative corresponds to BG - Br . Integration of these peaks showed 
units after background subtraction . For visual illustrations of about 70 % yield of BG - Br from the reaction mixture . 
fluorescence signals , color maps are generated using Matlab BG - Br was then coupled to the amines of the chitosan 
( Mathworks , Natick , Mass . ) . 50 backbone through nucleophilic substitution . 
Histopathological Evaluation and Hematology Assay . 
Whole organs ( brain , liver , kidney , and spleen ) of Example 3 
C57BL / 6 mice were removed through necropsy 120 hrs after 
intravenous injection of nanoparticles or PBS and preserved Optimization of Crosslinked Coating 
in 10 % formalin for 48 hrs . Tissues were then embedded in 55 
paraffin wax , sliced into 5 um thick sections , and stained In this example , optimization of crosslinking of the NPCP 
with hematoxylin and eosin ( H & E ) or Prussian blue / Nuclear copolymer coating is described . 
Fast Red using standard clinical laboratory protocols . Optimization Procedure . 
Microscopic images of tissues were acquired using an E600 Disulfide bond formation was utilized to further stabilize 
upright microscope ( Nikon ) equipped with a CCD color 60 the NPCP for subsequent conjugation of BG , fluorescent 
camera . Blood cell panels and serum aspartate aminotrans - probes , and CTX , as well as provide a mechanism for release 
ferase ( AST ) and alanine aminotransferase ( ALT ) levels of drug within target cells . To optimize crosslinking , amine 
were quantified 120 hours after intravenous administration reactive Traut ' s reagent was reacted with NPCPs at 10 : 1 , 
of nanoparticles or free drug ( n = 3 per treatment condition ) , 5 : 1 , and 2 . 5 : 1 weight ratio Traut ' s reagent : iron . The stability 
and compared to mice receiving PBS injection ( n = 5 ) . Three 65 of the crosslinked NPCPs were compared to non - crosslinked 
hundred microliters of blood was drawn from each mouse NPCPs in PBS in terms of hydrodynamic size change over 
through cardiac heart puncture . Samples were then submit - time . Crosslinking dramatically stabilized the nanoparticle 
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at all three Traut ' s reagent ratios . Because the reaction with TABLE 3 
Traut ' s reagent consumes amines that are necessary for 
Hydrodynamic Size of Crosslinked Coating Nanoparticles . subsequent conjugations , the number of reactive amines of 
NPCP and NPCPx produced at the three crosslinking ratios Nanoparticle 
was determined and the results summarized in Table 2 . 5 ( Traut ' s reagent : iron ) Hydrodynamic Size ( nm ) ( over 5 days ) 
TABLE 2 25 - 55 25 
NPCP 
NPCPx ( 10 : 1 ) 
NPCPx ( 5 : 1 ) 
NPCPx ( 2 . 5 : 1 ) Amine groups / Nanoparticle of Crosslinked Coating Nanoparticles . 10 
Nanoparticle ( Traut ’ s reagent : iron ) Amine groups / nanoparticle 
564 
The results illustrate the stability of the nanoparticles 
having crosslinked copolymer coating . 
While illustrative embodiments have been illustrated and 
15 described , it will be appreciated that various changes can be 
made therein without departing from the spirit and scope of 
the invention . 
NPCP 
NPCPx ( 10 : 1 ) 
NPCPx ( 5 : 1 ) 
NPCPx ( 2 . 5 : 1 ) 
355 
372 
554 
The embodiments of the invention in which an exclusive 
These results show that at the 2 . 5 : 1 ratio , only a small 20 property or privilege is claimed are defined as follows : 1 . A nanoparticle , comprising : fraction of available amines are consumed by Traut ' s ( a ) a core having a surface and comprising a core material ; reagent , indicating that few disulfide bonds could be formed ( b ) a coating on the surface of the core , the coating 
at this ratio . Both the 5 : 1 and 10 : 1 ratio show a significant comprising a crosslinked copolymer comprising a chi 
drop in the number of amines indicating a greater number of 25 tosan and a poly ( ethylene oxide ) oligomer , wherein the 
thiols for disulfide bond formation , while maintaining an crosslinked polymer comprises crosslinks that are dis 
adequate number of amines for further conjugation . Because ulfide crosslinks ; and 
there was not a significant gain in free thiols by increasing ( c ) O? - benzylguanine covalently coupled to the coating . 2 . The nanoparticle of claim 1 , wherein the core material the Traut ' s reagent ratio from 5 : 1 to 10 : 1 and further urter 30 is a magnetic material . 
experiments showed that the 2 . 5 : 1 ratio was not consistent 3 . The nanoparticle of claim 1 . wherein the core material 
in stabilizing NPCPs , the 5 : 1 ratio was determined to be is selected from the group consisting of ferrous oxide , ferric 
optimal . oxide , silicon oxide , polycrystalline silicon oxide , silicon 
Characterization of NPCP Crosslinking . Hydrodynamic nitride , aluminum oxide , germanium oxide , zinc selenide , 35 tin dioxide , titanium , titanium dioxide , nickel titanium , sizes of NPCP and NPCPx crosslinked at 10 : 1 , 5 : 1 or 2 . 5 : 1 indium tin oxide , gadolinium oxide , stainless steel , gold , and weight ratio of 2 - iminothiolane to iron was analyzed at 100 mixtures thereof . ug / mL in PBS ( pH 7 . 4 ) using a DTS Zetasizer Nano 4 . The nanoparticle of claim 1 , wherein the copolymer is ( Malvern Instruments , Worcestershire , UK ) . Quantification a graft copolymer having a chitosan backbone and poly 
of the number of amine groups immobilized on the surface 40 ( ethylene oxide ) oligomer side chains . 
of NPCP and NPCPx was performed by reaction of N - suc 5 . The nanoparticle of claim 1 , wherein the number of 
cinimidyl 3 - ( 2 - pyridyldithio ) propionate ( SPDP ) ( 4 . 3 mg ) to O? - benzylguanines / nanoparticle is from about 50 to about 
NPCP / NPCPx ( 2 mg ) for 2 hrs at room temperature to 2000 . 
produce pyridyldithiol - activated NPCP / NPCPx . Pyridyldi - 6 . The nanoparticle of claim 1 having a mean core size 
thiol - activated NPCP / NPCPx was purified using size exclu - 45 from about 2 to about 25 nm . 
sion chromatography in S - 200 resin into 100 mM boric acid 7 . The nanoparticle of claim 1 having a hydrodynamic 
buffer , pH 7 . 4 . Purified pyridyldithiol - activated NPCP ) size from about 30 to about 250 nm . 
NPCPx was then mixed with tris - ( carboxyethyl ) phosphine 8 . The nanoparticle of claim 1 further comprising a 
hydrochloride ( TCEP ) at a final TCEP concentration of 50 targeting agent . 
mM . The NP / TCEP solution was reacted on a rocker for 30 50 9 . The nanoparticle of claim 8 , wherein the targeting agent 
minutes at room temperature . Cleaved pyridine - 2 - thiol is chlorotoxin , or a variant or derivative thereof . 
( P2T ) was separated from the reaction mixture ( 0 . 5 mL ) 10 . The nanoparticle of claim 1 further comprising a 
using a 30 kDa MW cut off Amicon Ultra centrifugal filter diagnostic agent . 
( Millipore , Billerica , Mass . ) centrifuged at 12 , 000 rcf for 10 11 . A composition , comprising a nanoparticle of claim 1 
minutes . The UV - vis absorbance spectra of the P2T rich » 55 and a carrier suitable for administration to a subject . 12 . A method for introducing Oº - benzyguanine into a cell supernatant was measured at 343 nm and quantified using comprising contacting a cell with a nanoparticle of claim 1 . 
extinction coefficient of 8080 cm - ? . The concentration of 13 . A method for detecting cells or tissues by magnetic P2T is equivalent to the concentration of reactive amines . resonance imaging , comprising : The number of amines / NPCP was determined by measuring 60 termined by measuring 60 ( a ) contacting cells or tissues of interest with a nanopar 
Fe concentration of the reaction mixture and calculating the ticle having affinity and specificity for the cells or 
molar concentration of NPCP assuming the nanoparticle has tissues of interest , wherein the nanoparticle of claim 1 ; 
a core diameter of 7 . 5 nm and the density of bulk magnetite . and 
Stability ( hydrodynamic size ) over 5 days of NPCP and ( b ) measuring the level of binding of the nanoparticle , 
NPCPx crosslinked at 10 : 1 , 5 : 1 and 2 . 5 : 1 weight ratio of 65 wherein an elevated level of binding , relative to normal 
Traut ' s reagent to iron was determined in PBS and the result cells or tissues , is indicative of binding to the cells or 
summarized in Table 3 . tissues of interest . 
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14 . A method for inhibiting O? - methylguanine - DNA 
methyltransferase ( MGMT ) in a subject , comprising admin 
istering a nanoparticle of claim 1 to the subject . 
15 . A method for treating a disease or condition treatable 
by inhibiting 0° - methylguanine - DNA methyltransferase 5 
( MGMT ) , comprising administering a therapeutically effec 
tive amount of a nanoparticle of claim 1 to a subject in need 
thereof . 
16 . A method for treating a brain cancer , comprising 
administering a therapeutically effective amount of a nano - 10 
particle of claim 1 to a subject in need thereof . 
17 . A method for treating a brain cancer , comprising 
administering a therapeutically effective amount of TMZ 
and a therapeutically effective amount of a nanoparticle of 
claim 1 to a subject in need thereof . 
18 . The nanoparticle of claim 8 further comprising a 
diagnostic agent . 
19 . A nanoparticle , comprising : 
( a ) a core having a surface and comprising a core material ; ( b ) a coating on the surface of the core , the coating 20 
comprising a crosslinked copolymer comprising a chi 
tosan and a poly ( ethylene oxide ) oligomer , wherein the 
crosslinked copolymer comprises disulfide crosslinks ; ( c ) O® - benzylguanine covalently coupled to the coating ; 
and 25 
( d ) chlorotoxin , or a variant or derivative thereof , cova lently coupled to the coating . 
25 
* * * * * 
